MedTrace Logo

Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years

NCT01396889 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-07-22

No results posted yet for this study

Summary

Acute upper respiratory tract infections are the most commmon infections in children and are associated with complications such as acute otitis media, sinusitis and pneumonia. Echinacea is widely used for treatment of upper respiratoty tract infections. The aim of this study is to evaluate its efficacy as prophilaxis in children 1-5 years old.

Conditions

  • Upper Respiratory Tract Infections

Interventions

DRUG

Echinacea

0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old

DRUG

Placebo

Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months

Sponsors & Collaborators

  • Hormozgan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Roya Firoozi, Resident · Hormozgan University of Medical Sciences (HUMS)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-12-31
Completion
2011-07-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01396889 on ClinicalTrials.gov